# Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

> **NCT02681302** · PHASE1,PHASE2 · TERMINATED · sponsor: **Hackensack Meridian Health** · enrollment: 46 (actual)

## Conditions studied

- Multiple Myeloma
- Lymphoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02681302
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-07
- **Primary completion:** 2024-05-10
- **Final completion:** 2024-05-10
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Lack of Accrual
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02681302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02681302, "Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02681302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*